<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hypoglycemia in children and adolescents with type 1 diabetes mellitus</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hypoglycemia in children and adolescents with type 1 diabetes mellitus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hypoglycemia in children and adolescents with type 1 diabetes mellitus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynne L Levitsky, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Madhusmita Misra, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph I Wolfsdorf, MD, BCh</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1570476817"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypoglycemia is a common complication of type 1 diabetes mellitus (T1DM) in childhood [<a href="#rid1">1</a>]. It can occur in any child in whom the dose of administered insulin exceeds the insulin requirement. Avoiding severe and recurrent hypoglycemia is an important goal of diabetes management because these events can lead to acute and permanent neurologic complications. Fortunately, setting stringent targets for glycemic control generally does not increase the risk for severe hypoglycemic events and good glycemic control may improve cognitive development [<a href="#rid2">2,3</a>].</p><p>The symptoms, risk factors, prevention, and treatment of hypoglycemia in children and adolescents with T1DM are discussed in this topic review. Other issues in this population are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5816.html" rel="external">"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5817.html" rel="external">"Overview of the management of type 1 diabetes mellitus in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/129412.html" rel="external">"Insulin therapy for children and adolescents with type 1 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5818.html" rel="external">"Complications and screening in children and adolescents with type 1 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16412.html" rel="external">"Management of exercise for children and adolescents with type 1 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/5819.html" rel="external">"Management of type 1 diabetes mellitus in children during illness, procedures, school, or travel"</a>.)</p><p></p><p class="headingAnchor" id="H1570477263"><span class="h1">DEFINITIONS AND PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>An international consensus panel defined the following important thresholds for categorizing hypoglycemic episodes in children with T1DM [<a href="#rid3">3,4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical hypoglycemia alert – Blood glucose &lt;70 mg/dL (3.9 mmol/L); this is commonly used as a threshold for recognizing and initiating treatment for hypoglycemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinically important or serious hypoglycemia – Blood glucose &lt;54 mg/dL (3.0 mmol/L); values in this range tend to be associated with defective glucose counterregulation, impaired hypoglycemia awareness, and, sometimes, cognitive dysfunction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe hypoglycemia – An event associated with severe cognitive impairment (including coma and seizures), requiring assistance of another person to correct, including administration of carbohydrates or <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">glucagon</a> or intravenous (IV) dextrose.</p><p></p><p>Although these blood glucose thresholds are somewhat arbitrary because the clinical correlates vary among individuals and across age groups, they provide consistent definitions that can be applied to research and also match definitions proposed by an international consensus panel for hypoglycemia in adults [<a href="#rid5">5</a>].</p><p>Physiologic responses to hypoglycemia include increased secretion of the counterregulatory hormones <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">glucagon</a>, epinephrine, cortisol, and growth hormone. In individuals with T1DM, the counterregulatory hormone response often becomes blunted over time, so that the glucagon response is impaired and the epinephrine surge may be attenuated; this increases the risk of persistent hypoglycemia. Impairment of the epinephrine response occurs in 30 percent or more of children and adolescents whose diabetes is well controlled [<a href="#rid6">6</a>]. This is especially likely to occur in tightly controlled patients with frequent biochemical hypoglycemia. (See  <a class="medical medical_review" href="/z/d/html/1808.html" rel="external">"Physiologic response to hypoglycemia in healthy individuals and patients with diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H1570474902"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>The risk of hypoglycemia is associated with the following:</p><p class="headingAnchor" id="H1570474908"><span class="h2">Young age</span><span class="headingEndMark"> — </span>Hypoglycemic episodes are more common and severe in younger children because food intake, activity, and adherence to treatment schedules are less predictable in younger compared with older children. Aiming for very tight glycemic control can further increase the risk of hypoglycemia in this age group, although this risk can be reduced with the use of a continuous glucose monitoring (CGM) device together with a pump that has a predictive low glucose insulin suspend feature [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/5817.html" rel="external">"Overview of the management of type 1 diabetes mellitus in children and adolescents", section on 'Age-based care'</a>.)</p><p>In a large multicenter registry, severe hypoglycemia occurred in 9.6 percent of children 2 to &lt;6 years of age, as compared with 5.2 percent of those 6 to &lt;13 years and 6.3 percent of those 13 to &lt;18 years [<a href="#rid8">8</a>]. In a second observational study, the incidence of severe hypoglycemia decreased with age [<a href="#rid9">9</a>]. In girls &lt;7 years of age, 7 to 12 years of age, and ≥13 years of age, the frequency of hypoglycemia was 24, 19, and 14 episodes per 100 patient-years, respectively. Frequent recurrences of hypoglycemia occurred in a minority of patients, with 20 percent of patients accounting for 80 percent of episodes.</p><p class="headingAnchor" id="H1570474920"><span class="h2">Type of insulin regimen</span><span class="headingEndMark"> — </span>Insulin dosing regimens are an important predictor of the risk of hypoglycemia. In general, intensive insulin therapy has the advantage of improved glycemic control and probably also reduces the risk for hypoglycemia when appropriately administered. (See  <a class="medical medical_review" href="/z/d/html/129412.html" rel="external">"Insulin therapy for children and adolescents with type 1 diabetes mellitus", section on 'Value of an intensive regimen'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fixed-dose regimens</strong> – These insulin regimens consist of a fixed daily injection schedule using intermediate- and rapid- or short-acting insulins. The incidence of hypoglycemia in children treated with a fixed-dose regimen ranges between 20 and 60 episodes per 100 patient-years [<a href="#rid9">9-11</a>]. Such regimens are unlikely to achieve optimal glycemic control and have largely been replaced by intensive regimens in resource-abundant areas.</p><p></p><p class="bulletIndent1">A fixed-dose insulin regimen typically includes NPH (neutral protamine hagedorn), an intermediate-acting insulin, which peaks several hours after administration. Hypoglycemia can occur if adequate glucose is not available at the time of peak insulin effect. As an example, if NPH is given with dinner or at bedtime, nocturnal hypoglycemia may occur between 12 AM to 4 AM, when NPH effect peaks  (<a class="graphic graphic_table graphicRef61880" href="/z/d/graphic/61880.html" rel="external">table 1</a> and <a class="graphic graphic_figure graphicRef59453" href="/z/d/graphic/59453.html" rel="external">figure 1</a>). The risk is increased at night because sleep impairs the counterregulatory hormone responses to hypoglycemia. Similarly, a missed morning snack or delayed lunch may result in hypoglycemia as a consequence of the morning NPH insulin reaching its peak without concomitant food intake. Snacks between meals and at bedtime that contain complex carbohydrates (with fat to delay absorption) reduce the frequency and severity of hypoglycemic episodes in children receiving fixed-dose insulin regimens.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intensive regimens</strong> – In general, an insulin replacement regimen that delivers a basal insulin dose with intermittent boluses of rapid-acting insulin to cover food intake is associated with a lower risk of hypoglycemia than fixed-dose insulin regimens [<a href="#rid12">12-21</a>]. The risk for hypoglycemia has been examined for specific types of intensive insulin therapies:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Multiple daily injections (MDI)</strong> – Most regimens use a long-acting insulin analog (<a class="drug drug_pediatric" data-topicid="12633" href="/z/d/drug information/12633.html" rel="external">insulin glargine</a>, detemir, or degludec) to deliver insulin at a relatively consistent basal rate without a pronounced peak effect  (<a class="graphic graphic_table graphicRef61880" href="/z/d/graphic/61880.html" rel="external">table 1</a>). Boluses of a rapid-acting insulin such as lispro, aspart, or glulisine are given before meals and snacks or, sometimes, immediately after the meal or snack (particularly in very young children or when it is uncertain whether or not the child will finish the meal/snack). Observational studies have shown that this approach reduces the incidence of severe hypoglycemic episodes in all age groups, including children &lt;6 years of age, as compared with fixed insulin regimens. These data are discussed in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/129412.html" rel="external">"Insulin therapy for children and adolescents with type 1 diabetes mellitus", section on 'Multiple daily injections'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Insulin pump</strong> – Insulin pump therapy (also known as continuous subcutaneous insulin infusion) is an alternate form of intensive insulin therapy. The insulin pump provides a continuous subcutaneous infusion of rapid-acting insulin delivered at a basal rate, with boluses administered with meals and snacks. Controlled trials of insulin pump therapy in this age group generally suggest that it is similar to or somewhat better than MDI in achieving glycemic control and avoiding hypoglycemic episodes [<a href="#rid22">22,23</a>]. These data are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/129412.html" rel="external">"Insulin therapy for children and adolescents with type 1 diabetes mellitus", section on 'Insulin pump'</a>.)</p><p></p><p>When using either MDI or insulin pump therapy, administration of boluses of rapid-acting or short-acting insulin before the glucose-lowering effect of each dose has completely dissipated is referred to as "stacking" and may precipitate hypoglycemia. To prevent "stacking," patients should be counseled to wait at least three hours before administering another dose of rapid-acting insulin to correct hyperglycemia.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucose sensors and sensor-augmented pumps</strong> – Devices that may help to reduce rates of hypoglycemia include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CGM device</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Various types of sensor-augmented insulin pumps (open-loop systems), with low glucose suspension (suspend on low) or predictive low glucose management (suspend before low)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hybrid closed-loop insulin pump systems (sometimes called "artificial pancreases")</p><p></p><p class="bulletIndent1">These devices are described in more detail in a separate topic, including their performances for reducing hypoglycemia in children. (See  <a class="medical medical_review" href="/z/d/html/129412.html" rel="external">"Insulin therapy for children and adolescents with type 1 diabetes mellitus", section on 'Automated insulin delivery (hybrid closed-loop insulin pumps)'</a> and  <a class="medical medical_review" href="/z/d/html/129412.html" rel="external">"Insulin therapy for children and adolescents with type 1 diabetes mellitus", section on 'Insulin pumps with glucose sensors'</a>.)</p><p></p><p class="headingAnchor" id="H1570474926"><span class="h2">Exercise</span><span class="headingEndMark"> — </span>Exercise is a well-established cause of hypoglycemia because exercise enhances insulin sensitivity, increases utilization of glucose, and increases insulin absorption from the injection site due to increased blood flow. The hypoglycemic effects of exercise can be delayed several hours and can vary among individuals and with the intensity and duration of exercise.</p><p>Recommendations to avoid hypoglycemia during and after exercise include:</p><p class="bulletIndent1"><span class="glyph">●</span>Monitoring blood glucose before, during, and after vigorous activity. If this is a new activity, monitoring should be done up to 12 hours after physical activity because of possible delayed effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Consuming a snack before and/or during the time of increased activity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reducing the last insulin dose before activity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reducing the basal rate of the insulin pump (by setting a "temporary" basal rate) for the duration of exercise and for a variable period thereafter.</p><p></p><p>Automated systems to adjust insulin infusions may also reduce the risk of hypoglycemia during exercise. Preliminary studies suggest benefits from use of a predictive low glucose suspend system or a closed-loop control system [<a href="#rid24">24-26</a>]. (See  <a class="medical medical_review" href="/z/d/html/129412.html" rel="external">"Insulin therapy for children and adolescents with type 1 diabetes mellitus", section on 'Insulin pumps with glucose sensors'</a>.)</p><p>Exercise can cause paradoxical <strong>hyper</strong>glycemia under certain conditions, including high-intensity activity or competition, because of release of counterregulatory hormones from stress associated with the activity. Glycemic management during exercise is discussed in detail in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/16412.html" rel="external">"Management of exercise for children and adolescents with type 1 diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H2104752365"><span class="h2">Alcohol ingestion</span><span class="headingEndMark"> — </span>Alcohol ingestion is a common cause of hypoglycemic episodes in adolescents and young adults because it suppresses gluconeogenesis and glycogenolysis and acutely increases insulin sensitivity [<a href="#rid1">1</a>]. The combination of exercise with alcohol ingestion further increases the risk for severe hypoglycemia.</p><p class="headingAnchor" id="H1570474932"><span class="h2">Other risk factors</span></p><p class="bulletIndent1"><span class="glyph">●</span>Acute illness – During acute illnesses associated with nausea, vomiting, and anorexia, hypoglycemia may occur because of poor oral intake if the doses of insulin with meal-associated peaks are not appropriately adjusted. Hyperglycemia can also occur during acute illnesses because of peripheral insulin resistance. Frequent blood glucose monitoring is mandatory for insulin dose adjustment based upon the blood glucose measurements. In many cases, the insulin dose may need to be reduced, but it should only rarely be omitted entirely because hyperglycemia and diabetic ketoacidosis can develop if basal insulin is not given. (See  <a class="medical medical_review" href="/z/d/html/5819.html" rel="external">"Management of type 1 diabetes mellitus in children during illness, procedures, school, or travel", section on 'Sick-day management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inconsistent carbohydrate intake – Variations in the timing and carbohydrate content of food intake result in erratic glycemic effects and an increased risk of hypoglycemia. Children who are on a fixed insulin regimen are particularly vulnerable if the schedule and carbohydrate content of meals are not consistent, because insulin doses will not match glycemic needs. (See  <a class="medical medical_review" href="/z/d/html/1765.html" rel="external">"Nutritional considerations in type 1 diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Psychological and socioeconomic factors – Increased risk of hypoglycemia is associated with lower socioeconomic status [<a href="#rid9">9</a>] and psychiatric disorders. (See  <a class="medical medical_review" href="/z/d/html/5818.html" rel="external">"Complications and screening in children and adolescents with type 1 diabetes mellitus", section on 'Psychiatric disorders'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coexisting autoimmune disorders – Celiac disease, Addison's disease, and autoimmune thyroiditis are associated with T1DM and may increase the risk of hypoglycemia. These disorders should be excluded in children with recurrent unexplained hypoglycemia. (See  <a class="medical medical_review" href="/z/d/html/5823.html" rel="external">"Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus"</a>.)</p><p></p><p class="headingAnchor" id="H594062680"><span class="h1">PREVENTION AND ANTICIPATORY GUIDANCE</span></p><p class="headingAnchor" id="H2227645878"><span class="h2">Targets for glycemic control</span><span class="headingEndMark"> — </span>A target for hemoglobin A1c (A1C) of &lt;7 percent (53 mmol/mol) is recommended for most children and adolescents who have access to comprehensive diabetes care, but a more or less stringent target may be appropriate for an individual patient [<a href="#rid1">1,27</a>]. These stringent A1C targets improve glycemic control without significantly increasing the risk for severe hypoglycemia. Considerations for setting an A1C target in individual patients are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/129412.html" rel="external">"Insulin therapy for children and adolescents with type 1 diabetes mellitus", section on 'Target for hemoglobin A1c'</a>.)</p><p class="headingAnchor" id="H3372706604"><span class="h2">Fear of hypoglycemia</span><span class="headingEndMark"> — </span>Fear of hypoglycemia on the part of the child, caregiver, or provider can result in poor glycemic control. Some children and parents who are concerned about hypoglycemia may keep blood glucose values above recommended targets in an effort to avoid hypoglycemic episodes [<a href="#rid28">28-31</a>]. Counseling about this issue and careful attention to accurate insulin dose calculations should be an important part of diabetes management [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H2570906616"><span class="h2">Neurologic sequelae</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute effects of hypoglycemia</strong> – Hypoglycemia clearly has short-term effects on cognitive function. Even mild hypoglycemia can affect critical activities, such as driving or performance in standardized school examinations, and reduce mental efficiency, including attention, memory, and performance on mathematical tasks [<a href="#rid33">33-36</a>].</p><p></p><p class="bulletIndent1">Severe hypoglycemia is associated with neurologic impairment, which occasionally includes acute and transient cortical blindness [<a href="#rid37">37,38</a>]. Stroke-like hemiparesis can occur and persist for up to 24 hours after a severe episode. These functional changes are accompanied by altered findings on the electroencephalogram and increases in regional cerebral blood flow [<a href="#rid39">39</a>]. Prolonged severe hypoglycemia is responsible for 5 to 10 percent of deaths in patients with T1DM [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic effects of hypoglycemia</strong> – Concerns have been raised that severe or repeated episodes of hypoglycemia may have deleterious effects on brain development and learning, particularly in young children [<a href="#rid41">41-44</a>]. Therefore, avoidance of these episodes is an important goal of diabetes management, especially in young children. Fortunately, studies of children and adults using modern methods of diabetes management provide some reassurance that moderate episodes of hypoglycemia probably are not associated with long-term cognitive sequelae [<a href="#rid40">40,45-47</a>]. As an example, in a population-based study of children with T1DM in Denmark, there were no differences in standardized tests for reading and mathematics between children with and those without T1DM [<a href="#rid47">47</a>]. In addition, children with onset of T1DM before six years of age or those with diabetes duration of more than four years did not have significantly different test scores compared with children without T1DM. Sixty-four percent of the children used an insulin pump, and those with tight glucose control had better test scores than those with poor control. Similarly, among adults and adolescents enrolled in the Diabetes Control and Complications Trial (DCCT), neither tight glucose control (intensive therapy) nor recurrent severe hypoglycemia were associated with cognitive deficits after an average of 6.5 years of follow-up [<a href="#rid48">48</a>]. Long-term follow-up of the DCCT cohort after 18 years of therapy still revealed no association between cognitive function and frequency of episodes of hypoglycemia [<a href="#rid49">49</a>]. These findings contrast with earlier studies in which earlier onset of T1DM was associated with an increased risk for mild neuropsychological dysfunction [<a href="#rid50">50-55</a>].</p><p></p><p class="bulletIndent1">Although early onset of T1DM may be associated with an increased risk for neuropsychological dysfunction and structural changes in the brain, it is not clear that these effects are mediated by chronic or acute severe episodes of hypoglycemia. Indeed, some studies suggest that chronic <strong>hyper</strong>glycemia may be responsible for cognitive dysfunction [<a href="#rid43">43,56-58</a>] and children with a history of diabetic ketoacidosis have lower rates of accurate memory on structured tasks than those without a history of diabetic ketoacidosis [<a href="#rid59">59,60</a>]. These observations led to the current clinical approach to glycemic management of T1DM, which recommends more stringent glycemic targets, provided that episodes of severe hypoglycemia can be avoided [<a href="#rid3">3,27,57</a>]. (See <a class="local">'Targets for glycemic control'</a> above.)</p><p></p><p class="headingAnchor" id="H4099723482"><span class="h2">Hypoglycemia unawareness</span><span class="headingEndMark"> — </span>"Hypoglycemia unawareness" is a condition characterized by a lack of warning symptoms of hypoglycemia because of blunting of the sympathetic neural activation and epinephrine response (see <a class="local">'Definitions and pathophysiology'</a> above). This is more commonly seen in children with long duration of diabetes and increases the risk of severe and/or recurrent hypoglycemia. Any episode of hypoglycemia can lower the glucose threshold at which adrenergic discharge and symptoms occur, increasing the risk for subsequent severe hypoglycemia. Prevention of hypoglycemia for a few weeks can restore hypoglycemia awareness.</p><p class="headingAnchor" id="H3149460447"><span class="h2">Preparation for hypoglycemic episodes</span><span class="headingEndMark"> — </span>Key precautions for all patients with T1DM are:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral glucose</strong> – Always have ready access to a concentrated and rapidly absorbed simple carbohydrate food source, such as sweetened fruit juice, glucose tablets, or cake frosting. (See <a class="local">'Mild and moderate hypoglycemia'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucagon</strong> – Have a <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">glucagon</a> kit at home, at school/daycare, and in the car during long journeys. Prescriptions should be refilled before the date of expiration. (See <a class="local">'Glucagon'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medical identification</strong> – Wear an identification band to ensure appropriate intervention by emergency personnel should such a situation arise. <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.medicalert.org%2F&amp;token=5yLNPmHjkOhvnhOBCCm6DAZPLoHBubhCOVCA0Ec1SmN4Jzha8TnBpGZDjKJd2Nmq&amp;TOPIC_ID=97229" target="_blank">MedicAlert</a> is a commonly used and excellent system.</p><p></p><p class="headingAnchor" id="H1846660870"><span class="h1">SYMPTOMS AND SIGNS</span><span class="headingEndMark"> — </span>Clinicians should inquire about symptoms of hypoglycemia during the routine care of a child with T1DM  (<a class="graphic graphic_table graphicRef97226" href="/z/d/graphic/97226.html" rel="external">table 2</a>). Identification of nocturnal hypoglycemia is particularly important, given reported incidences on any given night of 30 percent or more in children on insulin pump or multiple daily injections (MDI) and higher rates in young children or those using fixed-dose insulin regimens [<a href="#rid61">61-63</a>]. Symptoms can be subtle and include nightmares, restless sleep, and, upon awakening, headache, confusion, or behavior changes. Decreased release of counterregulatory hormones during sleep and/or delayed hypoglycemic response to afternoon exercise may contribute to the risk for nocturnal hypoglycemia [<a href="#rid64">64</a>].</p><p>Nocturnal hypoglycemia is readily identified by continuous glucose monitoring (CGM) devices, and the frequency of episodes can be decreased in children using such devices, especially when linked to pumps with a suspend infusion function or partial closed loop.</p><p>Symptoms of hypoglycemia include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adrenergic symptoms</strong> – Tremor, pallor, rapid heart rate, palpitations, and diaphoresis. These are caused by sympathetic neural activation and epinephrine release [<a href="#rid65">65</a>]. However, episodes of hypoglycemia can lower the threshold at which these symptoms occur, leading to "hypoglycemia unawareness" and increasing the risk for subsequent severe hypoglycemia. (See <a class="local">'Hypoglycemia unawareness'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuroglycopenic symptoms</strong> – Fatigue, lethargy, headaches, behavior changes, drowsiness, unconsciousness, seizures, or coma. These symptoms result from direct effects of hypoglycemia on the central nervous system. The severity of neuroglycopenic symptoms increases with the severity of hypoglycemia and resultant central nervous system glucose deprivation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Behavioral symptoms</strong> – Behavioral symptoms include irritability, agitation, erratic behavior, unusual quietness, or tantrums and are most common in younger children. These behavioral symptoms are probably a consequence of adrenergic and neuroglycopenic responses [<a href="#rid1">1</a>].</p><p></p><p class="headingAnchor" id="H806351793"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Hypoglycemia may be symptomatic or can be detected by a low blood glucose concentration in the absence of symptoms. If a patient is symptomatic, measure blood glucose to confirm the suspected hypoglycemia. Families of children monitoring glycemia with continuous glucose monitoring (CGM) devices need to know that these devices measure the levels of glucose in interstitial fluid. Circulating blood glucose levels equilibrate with the levels in interstitial fluid with a lag time of 15 minutes or more. Thus, if the child has a rapid drop in circulating blood glucose concentration, they may become symptomatic before hypoglycemia is detected by the CGM device. If confirmation is not possible, treat presumptively for hypoglycemia.</p><p class="headingAnchor" id="H757712439"><span class="h2">Classification of severity</span><span class="headingEndMark"> — </span>The severity of hypoglycemia is classified by symptoms and the response needed for successful treatment [<a href="#rid1">1,40</a>]. Although these symptom patterns are common, children and their parents show poor ability to detect either high or low blood glucose levels based on symptoms alone. Therefore, regular and confirmatory blood glucose monitoring or CGM is important. (See <a class="local">'Management'</a> above and  <a class="medical medical_review" href="/z/d/html/129412.html" rel="external">"Insulin therapy for children and adolescents with type 1 diabetes mellitus", section on 'Blood glucose monitoring'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild symptoms</strong> – Symptoms of mild hypoglycemia include adrenergic and mild neuroglycopenic manifestations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Older children can generally recognize symptoms (headache, tremor, palpitations, diaphoresis) and adequately treat themselves with oral intake of a rapidly absorbed carbohydrate.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For infants and very young children, symptoms of hypoglycemia include poor feeding, lethargy, jitteriness, and hypotonia; these symptoms may appear over a range of blood glucose concentrations. Young children are unable to communicate symptoms to caregivers and may not have the same adrenergic signs as older children. Thus, caregivers need to be trained to recognize and treat nonspecific symptoms associated with hypoglycemia in this age group. (See <a class="local">'Definitions and pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate symptoms</strong> – Moderate symptoms consist of sufficient neurologic impairment such that a second person is needed to administer oral therapy. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe symptoms</strong> – Severe symptoms of hypoglycemia include neurologic impairment that precludes oral therapy, thus requiring intervention with intranasal, subcutaneous, or intramuscular <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">glucagon</a> or intravenous (IV) dextrose. Symptoms may progress to loss of consciousness, seizures, or coma.</p><p></p><p class="headingAnchor" id="H1570474944"><span class="h2">Mild and moderate hypoglycemia</span><span class="headingEndMark"> — </span>Patients with mild and moderate hypoglycemia (blood glucose &lt;70 mg/dL [3.9 mmol/L] and/or adrenergic and neuroglycopenic symptoms described above) should be treated orally with a concentrated and rapidly absorbed simple carbohydrate food source (10 to 15 g glucose). Options include:</p><p class="bulletIndent1"><span class="glyph">●</span>Glucose tablets – 5 g per tablet</p><p class="bulletIndent1"><span class="glyph">●</span>Glucose gel – 15 g per tube</p><p class="bulletIndent1"><span class="glyph">●</span>Fruit juice – 12 g carbohydrate per 4 oz (120 mL)</p><p class="bulletIndent1"><span class="glyph">●</span>Regular soda (not diet) – 12 g carbohydrate per 4 oz (120 mL)</p><p class="bulletIndent1"><span class="glyph">●</span>Honey – 17 g carbohydrate per 1 tablespoon (15 mL)</p><p class="bulletIndent1"><span class="glyph">●</span>Table sugar (granulated sugar) – 12.5 g sucrose per 1 tablespoon</p><p class="bulletIndent1"><span class="glyph">●</span>Skittles – 10 g carbohydrate (sucrose) per 10 candies</p><p></p><p>Glucose and sucrose (which is rapidly broken down to glucose and fructose) are more effective than fructose alone in treating hypoglycemia [<a href="#rid66">66</a>]. These simple carbohydrates rapidly raise the blood glucose concentration. A weight-based dose (0.3 to 0.6 g/kg) may also be used, depending on the blood glucose level; one study reported that this was a more effective strategy to treat symptomatic hypoglycemia in children and adults compared with non-weight-based dosing of glucose [<a href="#rid67">67</a>].</p><p>In children who use an insulin pump to deliver insulin and/or use a CGM device, this treatment is usually sufficient. By contrast, in children receiving a fixed dose of insulin, it may be necessary to follow this treatment with a snack that contains a carbohydrate, protein, and fat in order to sustain blood glucose levels, such as a peanut butter sandwich or a bagel with cream cheese or other fat and protein. Blood glucose should be checked again in 15 to 20 minutes to confirm that glucose values have normalized and to determine whether further intervention is necessary. The patient may need to eat additional carbohydrates until blood glucose concentrations are sustained above 100 mg/dL (5.6 mmol/L). Children managed with an insulin pump or a hybrid closed-loop system rarely require an extra snack; indeed, ingesting more carbohydrate than necessary to treat the hypoglycemia often leads to rebound hyperglycemia.</p><p>In patients with poor oral intake during gastroenteritis or other illnesses, minidose <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">glucagon</a> has been used effectively to prevent impending hypoglycemia or to treat mild hypoglycemia at home. </p><p>Dosing is as follows, using a standard U100 insulin syringe:</p><p class="bulletIndent1"><span class="glyph">●</span>Children ≤2 years of age – 2 "units" (20 micrograms) of <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">glucagon</a> given subcutaneously</p><p class="bulletIndent1"><span class="glyph">●</span>Children 2 years and older – 1 "unit" of <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">glucagon</a> (10 micrograms)/year of age up to 15 "units" (150 micrograms)</p><p></p><p>A second dose (at double the initial dose) is given if blood glucose does not increase in 30 minutes [<a href="#rid68">68,69</a>].</p><p class="headingAnchor" id="H1570474950"><span class="h2">Severe hypoglycemia</span><span class="headingEndMark"> — </span>Patients with severe neurologic symptoms who are unable to take oral therapy require intervention with <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">glucagon</a> and/or <a class="drug drug_pediatric" data-topicid="13222" href="/z/d/drug information/13222.html" rel="external">IV dextrose</a>.</p><p class="headingAnchor" id="H1409727975"><span class="h3">Glucagon</span><span class="headingEndMark"> — </span>Patients with significant neurologic impairment and/or who are unable to take oral glucose require urgent treatment with <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">glucagon</a>. Every person with T1DM should have a glucagon kit readily available at all times. (See <a class="local">'Preparation for hypoglycemic episodes'</a> above.)</p><p>Glucagon comes in several forms:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Standard (lyophilized) </strong><strong>glucagon</strong> – <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">Glucagon</a> may be administered subcutaneously or intramuscularly at the following doses:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>≤20 kg body weight – 0.5 mg (or 0.02 to 0.03 mg/kg)</p><p class="bulletIndent2"><span class="glyph">•</span>&gt;20 kg body weight – 1 mg</p><p></p><p class="bulletIndent1">The standard formulation of <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">glucagon</a> is unstable in solution; it is only available as a lyophilized powder that requires reconstitution with a diluent immediately before use.</p><p></p><p class="bulletIndent1">These doses of <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">glucagon</a> are usually sufficient to increase blood glucose within a few minutes. The glucagon dose must be followed by oral intake of concentrated carbohydrates immediately upon awakening from the confused state. This is because both severe hypoglycemia and glucagon may cause nausea and vomiting within 45 minutes to an hour.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intranasal </strong><strong>glucagon</strong> – Dosing for intranasal <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">glucagon</a> is:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>3 mg intranasally initially (for ages ≥4 years)</p><p class="bulletIndent2"><span class="glyph">•</span>Administer an additional 3 mg dose (using a new device) if there has been no glycemic response after 15 minutes</p><p></p><p class="bulletIndent1">Intranasal <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">glucagon</a> is a unique powder formulation that is delivered through a device designed for one-time use.</p><p></p><p class="bulletIndent1">The use of intranasal <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">glucagon</a> in children and adolescents is supported by results from a randomized trial and an observational study under "real-world" conditions [<a href="#rid70">70,71</a>]. The time course of the glycemic response is similar to that for intramuscularly administered glucagon. Data on intranasal glucagon in adults are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1805.html" rel="external">"Hypoglycemia in adults with diabetes mellitus", section on 'Without IV access'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dasiglucagon</strong> – <a class="drug drug_pediatric" data-topicid="131165" href="/z/d/drug information/131165.html" rel="external">Dasiglucagon</a> is a soluble <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">glucagon</a> analog that is available in a fixed-dose autoinjector, with dosing:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>0.6 mg (for ages ≥6 years), given subcutaneously via autoinjector</p><p></p><p class="bulletIndent1">Because <a class="drug drug_pediatric" data-topicid="131165" href="/z/d/drug information/131165.html" rel="external">dasiglucagon</a> does not require reconstitution, it should be easier to administer in the stressful circumstances associated with the emergency treatment of severe hypoglycemia (seizure or loss of consciousness). Dasiglucagon is approved in the United States for individuals six years and older; the safety profile of this fixed dose in children and adolescents is similar to that of <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">glucagon</a> [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stable liquid </strong><strong>glucagon</strong> – A stable premixed liquid form of <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">glucagon</a> is available in the following doses:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>2 to 12 years – 0.5 mg</p><p class="bulletIndent2"><span class="glyph">•</span>≥12 years – 1 mg</p><p></p><p class="bulletIndent1">This stable liquid form is available as an autoinjector or prefilled syringe (Gvoke), which is approved in the United States for individuals two years and older [<a href="#rid73">73</a>]. It does not require refrigeration, and the medication is administered subcutaneously.</p><p></p><p class="headingAnchor" id="H3958975952"><span class="h3">Intravenous dextrose</span><span class="headingEndMark"> — </span>For patients with severe hypoglycemia, <a class="drug drug_pediatric" data-topicid="13222" href="/z/d/drug information/13222.html" rel="external">IV dextrose</a> should be given if IV access and appropriately trained medical personnel are available.</p><p>Dosing is 0.25 g/kg (maximum single dose 25 g). This is supplied by:</p><p class="bulletIndent1"><span class="glyph">●</span>2.5 mL/kg of 10% dextrose solution <strong>or</strong></p><p class="bulletIndent1"><span class="glyph">●</span>1 mL/kg of 25% dextrose solution</p><p></p><p>An IV infusion sufficient to maintain glucose can be started if the child is still unable to take orally. An infusion of 10% glucose at a maintenance rate may be required and can be titrated up or down based upon the blood glucose, which should be checked every 30 minutes initially. Electrolytes should be included in the IV fluids if the infusion is prolonged (eg, one hour or more).</p><p class="headingAnchor" id="H2702419394"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111575.html" rel="external">"Society guideline links: Diabetes mellitus in children"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/117462.html" rel="external">"Society guideline links: Hypoglycemia in infants and children"</a>.)</p><p class="headingAnchor" id="H1570482586"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15401.html" rel="external">"Patient education: Type 1 diabetes (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16597.html" rel="external">"Patient education: My child has diabetes: How will we manage? (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16598.html" rel="external">"Patient education: Managing blood sugar in children with diabetes (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16602.html" rel="external">"Patient education: Carb counting for children with diabetes (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16599.html" rel="external">"Patient education: Managing diabetes in school (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16600.html" rel="external">"Patient education: Giving your child insulin (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16601.html" rel="external">"Patient education: Checking your child's blood sugar level (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/85799.html" rel="external">"Patient education: Should I switch to an insulin pump? (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the basics topics (see  <a class="medical medical_patient" href="/z/d/html/1736.html" rel="external">"Patient education: Type 1 diabetes: Overview (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1570476901"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Risk factors for hypoglycemia in children with type 1 diabetes mellitus (T1DM) include younger age, a split-mixed insulin regimen with a fixed daily insulin schedule, increased vigorous activity (exercise), alcohol ingestion, acute illnesses, and depression. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Blood glucose thresholds for categorizing hypoglycemia</strong> – In children with T1DM, an alert value for hypoglycemia is defined as blood glucose &lt;70 mg/dL (3.9 mmol/L). Clinically important hypoglycemia is defined as blood glucose &lt;54 mg/dL (3.0 mmol/L). (See <a class="local">'Definitions and pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention and anticipatory guidance</strong> – Counseling to children and families includes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Good glycemic control using modern methods for insulin administration, insulin analogs, and frequent blood glucose monitoring (including continuous glucose monitoring [CGM]) does not increase the risk for hypoglycemia or long-term cognitive sequelae. However, severe or repeated episodes of hypoglycemia may have deleterious effects on brain development and learning, particularly in young children, and should be avoided. (See <a class="local">'Neurologic sequelae'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>"Hypoglycemia unawareness" is a condition characterized by a lack of warning symptoms of hypoglycemia because of blunting of the sympathetic neural and epinephrine response to hypoglycemia. This is more commonly seen in children with long duration of diabetes and recurrent episodes of hypoglycemia and increases the risk of severe hypoglycemia. (See <a class="local">'Hypoglycemia unawareness'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Important precautions for all individuals with T1DM include having ready access to a concentrated and rapidly absorbed simple carbohydrate food source, having a <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">glucagon</a> kit at home and wherever they spend time, and wearing a medical alert that identifies them as having T1DM. (See <a class="local">'Preparation for hypoglycemic episodes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical classification of severity</strong> – Because the clinical response to hypoglycemia varies, hypoglycemia is further classified by severity of symptoms and the response needed for successful treatment of the patient. (See <a class="local">'Classification of severity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mild symptoms of hypoglycemia include tremor, palpitations, diaphoresis, headaches, and behavior changes. There is little or no functional impairment, and older children can treat themselves with oral intake of a rapidly absorbed carbohydrate.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Moderate neurologic symptoms consist of sufficient neurologic impairment such that a second person has to administer oral therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe neurologic symptoms consist of unresponsiveness, seizures, or coma, such that the patient is unable to take oral therapy and requires subcutaneous administration of <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">glucagon</a> or administration of intravenous (IV) dextrose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of hypoglycemia</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients who can take oral therapy</strong> – Patients with mild and moderate neurologic symptoms should be treated promptly with a concentrated and rapidly absorbed simple carbohydrate food source, such as fruit juice, glucose tablets, Skittles candy, or cake frosting. In children who use an insulin pump and/or a CGM device, this treatment is usually sufficient. However, children on a fixed-dose insulin regimen may require an additional longer-lasting snack containing carbohydrate, fat, and protein in order to sustain a normal blood glucose level. Blood glucose should be checked again in 15 to 20 minutes to confirm that glucose values have normalized and to determine whether further intervention is necessary. (See <a class="local">'Mild and moderate hypoglycemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients who cannot take oral therapy</strong> – Patients with severe neurologic impairment require prompt treatment with <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">glucagon</a> or <a class="drug drug_pediatric" data-topicid="13222" href="/z/d/drug information/13222.html" rel="external">IV dextrose</a> (see <a class="local">'Severe hypoglycemia'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For standard (lyophilized) <a class="drug drug_pediatric" data-topicid="13335" href="/z/d/drug information/13335.html" rel="external">glucagon</a>, give 0.02 to 0.03 mg/kg (maximum dose 1 mg). Different doses are used for other formulations of glucagon (stable liquid form [fixed-dose], intranasal, or a soluble liquid analog [<a class="drug drug_pediatric" data-topicid="131165" href="/z/d/drug information/131165.html" rel="external">dasiglucagon</a>]). (See <a class="local">'Glucagon'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For <a class="drug drug_pediatric" data-topicid="13222" href="/z/d/drug information/13222.html" rel="external">IV dextrose</a>, give 2.5 mL/kg of 10% dextrose solution <strong>or</strong> 1 mL/kg of 25% dextrose solution (both are equivalent to 0.25 g/kg; maximum single dose 25 g). (See <a class="local">'Intravenous dextrose'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Abraham MB, Karges B, Dovc K, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Assessment and management of hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes 2022; 23:1322.</a></li><li><a class="nounderline abstract_t">Mauras N, Buckingham B, White NH, et al. Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study. Diabetes Care 2021; 44:983.</a></li><li><a class="nounderline abstract_t">de Bock M, Codner E, Craig ME, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. Pediatr Diabetes 2022; 23:1270.</a></li><li><a class="nounderline abstract_t">Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28:1245.</a></li><li><a class="nounderline abstract_t">International Hypoglycaemia Study Group. Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2017; 40:155.</a></li><li><a class="nounderline abstract_t">Diabetes Research in Children Network (DirecNet) Study Group, Tsalikian E, Tamborlane W, et al. Blunted counterregulatory hormone responses to hypoglycemia in young children and adolescents with well-controlled type 1 diabetes. Diabetes Care 2009; 32:1954.</a></li><li><a class="nounderline abstract_t">Alotaibi A, Al Khalifah R, McAssey K. The efficacy and safety of insulin pump therapy with predictive low glucose suspend feature in decreasing hypoglycemia in children with type 1 diabetes mellitus: A systematic review and meta-analysis. Pediatr Diabetes 2020; 21:1256.</a></li><li><a class="nounderline abstract_t">Cengiz E, Xing D, Wong JC, et al. Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry. Pediatr Diabetes 2013; 14:447.</a></li><li><a class="nounderline abstract_t">Rewers A, Chase HP, Mackenzie T, et al. Predictors of acute complications in children with type 1 diabetes. JAMA 2002; 287:2511.</a></li><li><a class="nounderline abstract_t">Levine BS, Anderson BJ, Butler DA, et al. Predictors of glycemic control and short-term adverse outcomes in youth with type 1 diabetes. J Pediatr 2001; 139:197.</a></li><li><a class="nounderline abstract_t">Jones TW, Davis EA. Hypoglycemia in children with type 1 diabetes: current issues and controversies. Pediatr Diabetes 2003; 4:143.</a></li><li><a class="nounderline abstract_t">Dixon B, Peter Chase H, Burdick J, et al. Use of insulin glargine in children under age 6 with type 1 diabetes. Pediatr Diabetes 2005; 6:150.</a></li><li><a class="nounderline abstract_t">Alemzadeh R, Berhe T, Wyatt DT. Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus. Pediatrics 2005; 115:1320.</a></li><li><a class="nounderline abstract_t">Colino E, López-Capapé M, Golmayo L, et al. Therapy with insulin glargine (Lantus) in toddlers, children and adolescents with type 1 diabetes. Diabetes Res Clin Pract 2005; 70:1.</a></li><li><a class="nounderline abstract_t">Berhe T, Postellon D, Wilson B, Stone R. Feasibility and safety of insulin pump therapy in children aged 2 to 7 years with type 1 diabetes: a retrospective study. Pediatrics 2006; 117:2132.</a></li><li><a class="nounderline abstract_t">Nimri R, Weintrob N, Benzaquen H, et al. Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study. Pediatrics 2006; 117:2126.</a></li><li><a class="nounderline abstract_t">Willi SM, Planton J, Egede L, Schwarz S. Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. J Pediatr 2003; 143:796.</a></li><li><a class="nounderline abstract_t">Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care 2003; 26:1142.</a></li><li><a class="nounderline abstract_t">Weinzimer SA, Ahern JH, Doyle EA, et al. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report. Pediatrics 2004; 114:1601.</a></li><li><a class="nounderline abstract_t">Litton J, Rice A, Friedman N, et al. Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr 2002; 141:490.</a></li><li><a class="nounderline abstract_t">Murphy NP, Keane SM, Ong KK, et al. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003; 26:799.</a></li><li><a class="nounderline abstract_t">Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008; 25:765.</a></li><li><a class="nounderline abstract_t">Pańkowska E, Błazik M, Dziechciarz P, et al. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes 2009; 10:52.</a></li><li><a class="nounderline abstract_t">Abraham MB, Davey R, O'Grady MJ, et al. Effectiveness of a Predictive Algorithm in the Prevention of Exercise-Induced Hypoglycemia in Type 1 Diabetes. Diabetes Technol Ther 2016; 18:543.</a></li><li><a class="nounderline abstract_t">Dovc K, Macedoni M, Bratina N, et al. Closed-loop glucose control in young people with type 1 diabetes during and after unannounced physical activity: a randomised controlled crossover trial. Diabetologia 2017; 60:2157.</a></li><li><a class="nounderline abstract_t">Breton MD, Cherñavvsky DR, Forlenza GP, et al. Closed-Loop Control During Intense Prolonged Outdoor Exercise in Adolescents With Type 1 Diabetes: The Artificial Pancreas Ski Study. Diabetes Care 2017; 40:1644.</a></li><li><a class="nounderline abstract_t">American Diabetes Association Professional Practice Committee. 14. Children and Adolescents: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022; 45:S208.</a></li><li><a class="nounderline abstract_t">Marrero DG, Guare JC, Vandagriff JL, Fineberg NS. Fear of hypoglycemia in the parents of children and adolescents with diabetes: maladaptive or healthy response? Diabetes Educ 1997; 23:281.</a></li><li><a class="nounderline abstract_t">Green LB, Wysocki T, Reineck BM. Fear of hypoglycemia in children and adolescents with diabetes. J Pediatr Psychol 1990; 15:633.</a></li><li><a class="nounderline abstract_t">Clarke WL, Gonder-Frederick A, Snyder AL, Cox DJ. Maternal fear of hypoglycemia in their children with insulin dependent diabetes mellitus. J Pediatr Endocrinol Metab 1998; 11 Suppl 1:189.</a></li><li><a class="nounderline abstract_t">Patton SR, Dolan LM, Henry R, Powers SW. Parental fear of hypoglycemia: young children treated with continuous subcutaneous insulin infusion. Pediatr Diabetes 2007; 8:362.</a></li><li><a class="nounderline abstract_t">Barnard K, Thomas S, Royle P, et al. Fear of hypoglycaemia in parents of young children with type 1 diabetes: a systematic review. BMC Pediatr 2010; 10:50.</a></li><li><a class="nounderline abstract_t">McAulay V, Deary IJ, Ferguson SC, Frier BM. Acute hypoglycemia in humans causes attentional dysfunction while nonverbal intelligence is preserved. Diabetes Care 2001; 24:1745.</a></li><li><a class="nounderline abstract_t">Sommerfield AJ, Deary IJ, McAulay V, Frier BM. Short-term, delayed, and working memory are impaired during hypoglycemia in individuals with type 1 diabetes. Diabetes Care 2003; 26:390.</a></li><li><a class="nounderline abstract_t">Cox DJ, Gonder-Frederick LA, Kovatchev BP, et al. Progressive hypoglycemia's impact on driving simulation performance. Occurrence, awareness and correction. Diabetes Care 2000; 23:163.</a></li><li><a class="nounderline abstract_t">Gonder-Frederick LA, Zrebiec JF, Bauchowitz AU, et al. Cognitive function is disrupted by both hypo- and hyperglycemia in school-aged children with type 1 diabetes: a field study. Diabetes Care 2009; 32:1001.</a></li><li><a class="nounderline abstract_t">Mukamel M, Weitz R, Nissenkorn I, et al. Acute cortical blindness associated with hypoglycemia. J Pediatr 1981; 98:583.</a></li><li><a class="nounderline abstract_t">Garty BZ, Dinari G, Nitzan M. Transient acute cortical blindness associated with hypoglycemia. Pediatr Neurol 1987; 3:169.</a></li><li><a class="nounderline abstract_t">Ryan CM, Becker DJ. Hypoglycemia in children with type 1 diabetes mellitus. Risk factors, cognitive function, and management. Endocrinol Metab Clin North Am 1999; 28:883.</a></li><li><a class="nounderline abstract_t">Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013; 36:1384.</a></li><li><a class="nounderline abstract_t">Silverstein J, Klingensmith G, Copeland K, et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 2005; 28:186.</a></li><li><a class="nounderline abstract_t">Ho MS, Weller NJ, Ives FJ, et al. Prevalence of structural central nervous system abnormalities in early-onset type 1 diabetes mellitus. J Pediatr 2008; 153:385.</a></li><li><a class="nounderline abstract_t">Perantie DC, Lim A, Wu J, et al. Effects of prior hypoglycemia and hyperglycemia on cognition in children with type 1 diabetes mellitus. Pediatr Diabetes 2008; 9:87.</a></li><li><a class="nounderline abstract_t">Rovet JF, Ehrlich RM. The effect of hypoglycemic seizures on cognitive function in children with diabetes: a 7-year prospective study. J Pediatr 1999; 134:503.</a></li><li><a class="nounderline abstract_t">Wysocki T, Harris MA, Mauras N, et al. Absence of adverse effects of severe hypoglycemia on cognitive function in school-aged children with diabetes over 18 months. Diabetes Care 2003; 26:1100.</a></li><li><a class="nounderline abstract_t">Blasetti A, Chiuri RM, Tocco AM, et al. The effect of recurrent severe hypoglycemia on cognitive performance in children with type 1 diabetes: a meta-analysis. J Child Neurol 2011; 26:1383.</a></li><li><a class="nounderline abstract_t">Skipper N, Gaulke A, Sildorf SM, et al. Association of Type 1 Diabetes With Standardized Test Scores of Danish Schoolchildren. JAMA 2019; 321:484.</a></li><li><a class="nounderline abstract_t">Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial. Ann Intern Med 1996; 124:379.</a></li><li><a class="nounderline abstract_t">Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group, Jacobson AM, Musen G, et al. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007; 356:1842.</a></li><li><a class="nounderline abstract_t">Northam EA, Anderson PJ, Werther GA, et al. Neuropsychological complications of IDDM in children 2 years after disease onset. Diabetes Care 1998; 21:379.</a></li><li><a class="nounderline abstract_t">Rovet J, Alvarez M. Attentional functioning in children and adolescents with IDDM. Diabetes Care 1997; 20:803.</a></li><li><a class="nounderline abstract_t">Bjørgaas M, Gimse R, Vik T, Sand T. Cognitive function in type 1 diabetic children with and without episodes of severe hypoglycaemia. Acta Paediatr 1997; 86:148.</a></li><li><a class="nounderline abstract_t">Hershey T, Perantie DC, Warren SL, et al. Frequency and timing of severe hypoglycemia affects spatial memory in children with type 1 diabetes. Diabetes Care 2005; 28:2372.</a></li><li><a class="nounderline abstract_t">Wootton-Gorges SL, Glaser NS. Imaging of the brain in children with type I diabetes mellitus. Pediatr Radiol 2007; 37:863.</a></li><li><a class="nounderline abstract_t">Gaudieri PA, Chen R, Greer TF, Holmes CS. Cognitive function in children with type 1 diabetes: a meta-analysis. Diabetes Care 2008; 31:1892.</a></li><li><a class="nounderline abstract_t">Perantie DC, Wu J, Koller JM, et al. Regional brain volume differences associated with hyperglycemia and severe hypoglycemia in youth with type 1 diabetes. Diabetes Care 2007; 30:2331.</a></li><li><a class="nounderline abstract_t">Chiang JL, Kirkman MS, Laffel LM, et al. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 2014; 37:2034.</a></li><li><a class="nounderline abstract_t">Barnea-Goraly N, Raman M, Mazaika P, et al. Alterations in white matter structure in young children with type 1 diabetes. Diabetes Care 2014; 37:332.</a></li><li><a class="nounderline abstract_t">Ghetti S, Lee JK, Sims CE, et al. Diabetic ketoacidosis and memory dysfunction in children with type 1 diabetes. J Pediatr 2010; 156:109.</a></li><li><a class="nounderline abstract_t">Shehata G, Eltayeb A. Cognitive function and event-related potentials in children with type 1 diabetes mellitus. J Child Neurol 2010; 25:469.</a></li><li><a class="nounderline abstract_t">Kaufman FR, Austin J, Neinstein A, et al. Nocturnal hypoglycemia detected with the Continuous Glucose Monitoring System in pediatric patients with type 1 diabetes. J Pediatr 2002; 141:625.</a></li><li><a class="nounderline abstract_t">Beregszàszi M, Tubiana-Rufi N, Benali K, et al. Nocturnal hypoglycemia in children and adolescents with insulin-dependent diabetes mellitus: prevalence and risk factors. J Pediatr 1997; 131:27.</a></li><li><a class="nounderline abstract_t">Benkhadra K, Alahdab F, Tamhane SU, et al. Continuous subcutaneous insulin infusion versus multiple daily injections in individuals with type 1 diabetes: a systematic review and meta-analysis. Endocrine 2017; 55:77.</a></li><li><a class="nounderline abstract_t">Jones TW, Porter P, Sherwin RS, et al. Decreased epinephrine responses to hypoglycemia during sleep. N Engl J Med 1998; 338:1657.</a></li><li><a class="nounderline abstract_t">DeRosa MA, Cryer PE. Hypoglycemia and the sympathoadrenal system: neurogenic symptoms are largely the result of sympathetic neural, rather than adrenomedullary, activation. Am J Physiol Endocrinol Metab 2004; 287:E32.</a></li><li><a class="nounderline abstract_t">Husband AC, Crawford S, McCoy LA, Pacaud D. The effectiveness of glucose, sucrose, and fructose in treating hypoglycemia in children with type 1 diabetes. Pediatr Diabetes 2010; 11:154.</a></li><li><a class="nounderline abstract_t">McTavish L, Corley B, Weatherall M, et al. Weight-based carbohydrate treatment of hypoglycaemia in people with Type 1 diabetes using insulin pump therapy: a randomized crossover clinical trial. Diabet Med 2018; 35:339.</a></li><li><a class="nounderline abstract_t">Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care 2001; 24:643.</a></li><li><a class="nounderline abstract_t">Hartley M, Thomsett MJ, Cotterill AM. Mini-dose glucagon rescue for mild hypoglycaemia in children with type 1 diabetes: the Brisbane experience. J Paediatr Child Health 2006; 42:108.</a></li><li><a class="nounderline abstract_t">Sherr JL, Ruedy KJ, Foster NC, et al. Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes. Diabetes Care 2016; 39:555.</a></li><li><a class="nounderline abstract_t">Deeb LC, Dulude H, Guzman CB, et al. A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting. Pediatr Diabetes 2018; 19:1007.</a></li><li><a class="nounderline abstract_t">Battelino T, Tehranchi R, Bailey T, et al. Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial. Pediatr Diabetes 2021; 22:734.</a></li><li class="breakAll">Manufacturer's prescibing information for GVOKE, 8/2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212097s007lbl.pdf (Accessed on August 23, 2021).</li></ol></div><div id="topicVersionRevision">Topic 97229 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36537534" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : ISPAD Clinical Practice Consensus Guidelines 2022: Assessment and management of hypoglycemia in children and adolescents with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33568403" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36537523" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : ISPAD Clinical Practice Consensus Guidelines 2022: Glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15855602" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27872155" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19675205" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Blunted counterregulatory hormone responses to hypoglycemia in young children and adolescents with well-controlled type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32738022" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The efficacy and safety of insulin pump therapy with predictive low glucose suspend feature in decreasing hypoglycemia in children with type 1 diabetes mellitus: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23469984" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12020331" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Predictors of acute complications in children with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11487743" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Predictors of glycemic control and short-term adverse outcomes in youth with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14655273" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hypoglycemia in children with type 1 diabetes: current issues and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16109071" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Use of insulin glargine in children under age 6 with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15867042" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16126116" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Therapy with insulin glargine (Lantus) in toddlers, children and adolescents with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16740857" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Feasibility and safety of insulin pump therapy in children aged 2 to 7 years with type 1 diabetes: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16740856" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14657831" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12663587" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15574621" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12378187" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12610040" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18644063" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18761648" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27505305" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Effectiveness of a Predictive Algorithm in the Prevention of Exercise-Induced Hypoglycemia in Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28840263" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Closed-loop glucose control in young people with type 1 diabetes during and after unannounced physical activity: a randomised controlled crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28855239" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Closed-Loop Control During Intense Prolonged Outdoor Exercise in Adolescents With Type 1 Diabetes: The Artificial Pancreas Ski Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34964865" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : 14. Children and Adolescents: Standards of Medical Care in Diabetes-2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9257618" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Fear of hypoglycemia in the parents of children and adolescents with diabetes: maladaptive or healthy response?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2283572" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Fear of hypoglycemia in children and adolescents with diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9642659" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Maternal fear of hypoglycemia in their children with insulin dependent diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18036061" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Parental fear of hypoglycemia: young children treated with continuous subcutaneous insulin infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20633252" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Fear of hypoglycaemia in parents of young children with type 1 diabetes: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11574436" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Acute hypoglycemia in humans causes attentional dysfunction while nonverbal intelligence is preserved.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12547868" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Short-term, delayed, and working memory are impaired during hypoglycemia in individuals with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10868825" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Progressive hypoglycemia's impact on driving simulation performance. Occurrence, awareness and correction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19324943" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cognitive function is disrupted by both hypo- and hyperglycemia in school-aged children with type 1 diabetes: a field study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7205486" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Acute cortical blindness associated with hypoglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3508064" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Transient acute cortical blindness associated with hypoglycemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10609125" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Hypoglycemia in children with type 1 diabetes mellitus. Risk factors, cognitive function, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23589542" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15616254" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18534238" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Prevalence of structural central nervous system abnormalities in early-onset type 1 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18208449" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effects of prior hypoglycemia and hyperglycemia on cognition in children with type 1 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10190928" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The effect of hypoglycemic seizures on cognitive function in children with diabetes: a 7-year prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12663580" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Absence of adverse effects of severe hypoglycemia on cognitive function in school-aged children with diabetes over 18 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21572053" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The effect of recurrent severe hypoglycemia on cognitive performance in children with type 1 diabetes: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30721295" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Association of Type 1 Diabetes With Standardized Test Scores of Danish Schoolchildren.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8554246" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effects of intensive diabetes therapy on neuropsychological function in adults in the Diabetes Control and Complications Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17476010" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Long-term effect of diabetes and its treatment on cognitive function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9540019" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Neuropsychological complications of IDDM in children 2 years after disease onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9135946" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Attentional functioning in children and adolescents with IDDM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9055883" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cognitive function in type 1 diabetic children with and without episodes of severe hypoglycaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16186265" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Frequency and timing of severe hypoglycemia affects spatial memory in children with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17619872" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Imaging of the brain in children with type I diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18753668" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cognitive function in children with type 1 diabetes: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17575089" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Regional brain volume differences associated with hyperglycemia and severe hypoglycemia in youth with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24935775" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Type 1 diabetes through the life span: a position statement of the American Diabetes Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24319123" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Alterations in white matter structure in young children with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19833353" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Diabetic ketoacidosis and memory dysfunction in children with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19762507" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Cognitive function and event-related potentials in children with type 1 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12410189" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Nocturnal hypoglycemia detected with the Continuous Glucose Monitoring System in pediatric patients with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9255188" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Nocturnal hypoglycemia in children and adolescents with insulin-dependent diabetes mellitus: prevalence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27477293" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Continuous subcutaneous insulin infusion versus multiple daily injections in individuals with type 1 diabetes: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9614256" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Decreased epinephrine responses to hypoglycemia during sleep.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14970007" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hypoglycemia and the sympathoadrenal system: neurogenic symptoms are largely the result of sympathetic neural, rather than adrenomedullary, activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19663922" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The effectiveness of glucose, sucrose, and fructose in treating hypoglycemia in children with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29285796" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Weight-based carbohydrate treatment of hypoglycaemia in people with Type 1 diabetes using insulin pump therapy: a randomized crossover clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11315823" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16509909" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Mini-dose glucagon rescue for mild hypoglycaemia in children with type 1 diabetes: the Brisbane experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26884472" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29512902" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33934456" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
